Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Breast Neoplasms 3Urinary Bladder Neoplasms 1Ureteral Neoplasms 1Pancreatic Neoplasms 1Pain 1Ovarian Neoplasms 1Osteoporosis 1Neoplasms 1Neoplasm, Residual 1Myelodysplastic Syndromes 1Lymphoma 1Leukemia 1Kidney Neoplasms 1Giant Cell Tumor of Bone 1Depression 1Colonic Polyps 1Carcinoma, Transitional Cell 1Body Weight Changes 1Arthralgia 1Adenomatous Polyps 1

Interventions

Gemcitabine 83Cisplatin 59pembrolizumab 28Paclitaxel 21Nivolumab 21Carboplatin 21Cystectomy 20Docetaxel 18durvalumab 17atezolizumab 17Magnetic Resonance Spectroscopy 16Specimen Handling 15Radiotherapy 14avelumab 13Mitomycin 13Sunitinib 12Doxorubicin 12Methotrexate 11Fluorouracil 11Vinblastine 10Filgrastim 7BCG Vaccine 7Sorafenib 6Ipilimumab 6Immunoglobulin G 6Disulfides 6Biopsy 6enfortumab vedotin 5cabozantinib 5Trastuzumab 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Urinary Bladder Neoplasms × Calcium × Clear all
NCT03520231 2021-11-23

Study Comparing Denosumab With Standard Treatment in Urothelial Cancer Patients With Bone Metastases

University Health Network, Toronto

Phase 2 Completed
6 enrolled
Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Kidney Neoplasms, Ureteral Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡